Get the Stockscreener App
35.01
3.98%
1.34
Vera Therapeutics Inc stock is traded at $35.01, with a volume of 1.12M.
It is up +3.98% in the last 24 hours and down -6.19% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$33.67
Open:
$33.96
24h Volume:
1.12M
Relative Volume:
0.98
Market Cap:
$2.51B
Revenue:
-
Net Income/Loss:
$-368.95M
P/E Ratio:
-6.3135
EPS:
-5.5453
Net Cash Flow:
$-293.81M
1W Performance:
+10.72%
1M Performance:
-6.19%
6M Performance:
-27.86%
1Y Performance:
+65.53%
1-Day Range:
$33.69
$35.70
1-Week Range:
$31.05
$35.70
52-Week Range:
$19.07
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
35.01 | 2.46B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-16-25 | Initiated | BofA Securities | Buy |
| Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics (VERA) Receives a Buy from Wells Fargo - The Globe and Mail
Vera Therapeutics moves closer to full approval for kidney disease drug after FDA alignment - MSN
Will FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy Narrative - Yahoo Finance
CLDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial Analysis - Yahoo Finance
(VERA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail
Vera Therapeutics grants inducement awards to 10 new employees - scanx.trade
symbol__ Stock Quote Price and Forecast - CNN
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Grants Inducement Stock Awards to New Employees - Quiver Quantitative
Vera Therapeutics gives new hires 28,800 stock option shares - Stock Titan
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Goldman Sachs Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
Jefferies reiterates Vera Therapeutics stock rating on FDA alignment By Investing.com - Investing.com Canada
Vera Therapeutics stock gets Outperform rating from William Blair By Investing.com - Investing.com Canada
Vera Therapeutics advances FDA timeline for atacicept review - Investing.com UK
Why is Vera Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Vera Therapeutics Advances Atacicept for IgA Nephropathy with FDA Agreement - Intellectia AI
Wolfe Research reiterates Vera Therapeutics stock rating on regulatory path - Investing.com
Wolfe Research reiterates Vera Therapeutics stock rating on regulatory path By Investing.com - Investing.com Canada
Vera Therapeutics Gains FDA Alignment For Kidney Disease Drug, But Stock Drops - Stocktwits
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment - Yahoo Finance
Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval - marketscreener.com
Goldman Sachs reiterates Vera Therapeutics stock rating on FDA timeline By Investing.com - Investing.com Canada
Vera Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information and Nasdaq Listing - Minichart
Why is Vera Therapeutics stock sliding today? - Investing.com
Raymond James reiterates Strong Buy on Vera Therapeutics stock By Investing.com - Investing.com Canada
Vera Therapeutics advances FDA timeline for atacicept review By Investing.com - Investing.com Australia
Vera Therapeutics stock rating reiterated at Buy by TD Cowen on FDA alignment - Investing.com Canada
Vera Therapeut aligns with FDA on earlier ORIGIN 3 eGFR analysis; eGFR readout in Q3 2026 - TradingView
Atacicept approval path detailed by Vera Therapeutics (NASDAQ: VERA) - Stock Titan
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to ... - Caledonian Record
FDA, Vera move up kidney trial analysis for potential new IgA nephropathy drug - Stock Titan
VERA News | VERA THERAPEUTICS INC (NASDAQ:VERA) - ChartMill
Vera Therapeutics, Inc. Files Form 8-K Detailing Company Information and SEC Compliance (May 21, 2026) - Minichart
Liquidity Mapping Around (VERA) Price Events - Stock Traders Daily
Vera Therapeutics: Strong IgAN Data, But Differentiation Is Still Pending (NASDAQ:VERA) - Seeking Alpha
[8-K] Vera Therapeutics, Inc. Reports Material Event - Stock Titan
Director at Vera Therapeutics (VERA) receives 17,084 stock options with $34.35 strike - Stock Titan
[Form 4] Vera Therapeutics, Inc. Insider Trading Activity - Stock Titan
Vera Therapeutics (VERA) director Beth Seidenberg receives 17,084-share stock option grant - Stock Titan
Director at Vera Therapeutics (VERA) receives grant of 17,084 options - Stock Titan
Vera Therapeutics grants 17,084-share option to director | VERA Insider Trading - Stock Titan
Vera Therapeutics (VERA) director awarded options on 17,084 shares - Stock Titan
Vera Therapeutics (VERA) awards director 17,084 stock options - Stock Titan
Director Patrick Enright awarded 17,084 Vera Therapeutics (VERA) stock options - Stock Titan
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing - The Motley Fool
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $86 - Moomoo
BofA Securities Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden - Sahm
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):